Kiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024. In the quarter to June 2026, revenue grew 55.4%, EPS grew 37.5% and free cash flow grew 66.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for five.
Follow KNSA
Kiniksa Pharmaceuticals International, plc (KNSA) EV/Sales
As of 16 October 2026, Kiniksa Pharmaceuticals International, plc (KNSA) trades at a EV/Sales of 6.6×. Over the past ten years it has ranged from 0.0× (March 2022) to 9.1× (April 2022); the current reading is higher than 95% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.9× | 41.41% |
| FY2024 | 2.8× | (31.62%) |
| FY2023 | 4.0× | 9.64% |
| FY2022 | 3.7× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.3× | 23.67% |
| Mar 2026 | 4.3× | 9.19% |
| Dec 2025 | 3.9× | (8.37%) |
| Sep 2025 | 4.3× | 30.86% |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RGC Regencell Bioscience Holdings Limited compare | n/m |
| HIMS Hims & Hers Health, Inc. compare | 2.7× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 2.8× |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.9× |
| INDV Indivior Pharmaceuticals Inc. compare | 3.1× |
| LNTH Lantheus Holdings, Inc. compare | 4.2× |
| ALKS Alkermes plc compare | 4.6× |
| KNSA Kiniksa Pharmaceuticals International, plc | 6.6× |
| AMLX Amylyx Pharmaceuticals, Inc. compare | 30.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)